Navigation Links
Epeius Biotechnologies' Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer
Date:6/17/2009

SAN MARINO, Calif., June 17 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) announced today that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use as a second-line treatment for advanced or metastatic pancreatic cancer. The FDA Fast Track program, like Priority Review and Accelerated Approval, was implemented to facilitate the development and expedite the review of potentially important new drugs. The Fast Track Product designation, in particular, is granted following a critical evaluation of the "seriousness" or life-threatening nature of the unmet medical need, namely pancreatic cancer, and the potential of Rexin-G and its progressive clinical development to address this unmet need.

"This is an excellent affirmation of all that we have worked for," says Dr. Erlinda Maria Gordon, Medical Director of Epeius Biotechnologies, "and an important validation of our medical mission." Indeed, Rexin-G is the first in an entirely new class of targeted anti-cancer agents, with a sophistication that goes well beyond a simplistic antibody. Rexin-G is the flagship of tumor-targeted genetic medicine: "smart," "stealth," "selective" and "potent" nano-medicine that not only seeks out and accumulates in cancerous lesions that have spread throughout the body, but delivers a tumor-killing designer gene where it is needed most, selectively destroying tumor cells and their attendant blood supply, while sparing normal cells and healthy tissues. As presented at the 2009 ASCO G.I. Symposium, "Rexin-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer," documenting survival benefits, without toxicity, as monotherapy, when all else fails.

The FDA's timely decision to grant Rexin-G Fast Track Product Designation is not only validating in terms of the
'/>"/>

SOURCE Epeius Biotechnologies
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
2. Millennium Biotechnologies Reports Strong Third Quarter Revenue and Financial Results
3. Ezra Van Gelder Joins Microchip Biotechnologies as Executive Vice President R&D
4. Veteran of the Beverage Industry, Ken Sadowsky, Joins Millennium Biotechnologies Board of Directors
5. MDS Analytical Technologies Acquires Blueshift Biotechnologies
6. Millennium Biotechnologies Inc. Signs Five Year $20,000,000 Purchase Agreement with Provider Services Inc. of Cleveland, Ohio
7. VaxGen and Raven biotechnologies Announce Signing of Definitive Merger Agreement
8. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
9. FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G(R) for Osteosarcoma in California U.S.A.
10. STAAR Surgical Receives Japanese Clearance for the KS-Ni Preloaded IOL Injector System
11. Herzing University, Minneapolis Receives Board of Nursing Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... 18, 2013 After working diligently for months ... formally announced the integration of the fitment specs for ... is set to stun the automobile market with its extraordinary ... Genesis is marked as the latest entry in the ... lined up for the year 2013. , Aptly suiting ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Although obesity ... tumors, the association between obesity and esophageal adenocarcinoma, a ... other obesity-related tumors. As reported on Cancer.gov, ... are almost twice as likely as those of normal ... the relationship between obesity and esophageal cancer is not ...
(Date:5/18/2013)... May 18, 2013 Show And Go Training, ... various different training systems that is all about is getting ... the attention of http://ShowAndGoTrainingReview.com ’s Stan Stevenson, prompting ... is a unique “four phase system” designed to make you ... of time spent working out in the gym. The training ...
(Date:5/18/2013)... May 18, 2013 Losing weight remains to ... among the horde of new weight loss products available in ... about. Recent studies about this newest weight loss supplement prove ... body shape. , Garcinia Cambogia is a sub-tropical fruit that ... Eating the fruit can suppress a person’s appetite, while it ...
(Date:5/18/2013)... Newport Beach, CA (PRWEB) May 18, 2013 ... has recently announced the addition of a new member to ... hygienist who has worked in the field for over 10 ... she graduated with honors, and was elected a member of ... the dental hygiene profession. Marino enjoys working with patients of ...
Breaking Medicine News(10 mins):Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Show And Go Training: Review Examining Eric Cressy's Workout Program Revealed 2Health News:Lose Weight Without Dieting or Exercising with Garcinia Cambogia Select Now Available At HealthCareSupplementz.com 2Health News:Newport Beach Cosmetic Dentist John Ravera Adds New Member to Dental Team 2
... by Vitamin D, according to a study that says ... of the vitamin.// The vitamin is found in products ... Exposure to the sun is considered the most important ... Auckland’s researchers found that patients with higher concentrations of ...
... accident has been described as an environmental tragedy by the ... reportedly spewing out a toxic cocktail of chemicals.// Fears of ... led to the suspension of the firefighting efforts. The firemen ... been given. ,As many as 150 fire service ...
... is an improvement in the motor symptoms of patients ... cell implants from the human retina, according to a ... who suffer from the neurodegenerative disorder require the levodopa ... used for treating tremors and spasms. The levodopa medication ...
... 34% of the 12 year olds in Scotland are ... (ISD) has published this research conducted by the Government. ... // problems like diabetes, depression, osteoarthritis, back pain, low ... an expensive proposition to the NHS. ,The country’s ...
... care for treatment of chronic diseases reports various studies ... in the Journal of Palliative Medicine.// Palliative care is ... more works, it is mostly a symptomatic treatment given ... that there is a rapid increase in demand for ...
... soon be launched in Jharkhand for poor people in the ... from January next year. , ,A health department official ... rural areas in 22 districts where the poor are deprived ... equipped with x-ray, ECG and other testing machines and people ...
Cached Medicine News:Health News:Study Says Vitamin D Is Good For Lungs 2Health News:Firefighters Continue To Battle Blaze 2
(Date:5/17/2013)... 2013 /PRNewswire-iReach/ -- The escalation of new biological ... renewed emphasis on alternate delivery technologies. Alternate delivery ... of factors are converging to create both ... delivery device partners . These include new classes ... trend toward self-administration for chronic diseases, shifting patient ...
(Date:5/17/2013)... -- Atossa Genetics, Inc. (NASDAQ: ATOS ), The Breast ... , Chief Financial Officer & General Counsel, will present at ... 30, 2013, in New York City ... presentation is scheduled to begin at 3:30 p.m. EDT and ... webcast, go to www.atossagenetics.com . For more ...
(Date:5/16/2013)... ZURICH , May 17, 2013 ... Technology and Research (A*STAR) and Switzerland,s ... has been dosed in a Phase 1 clinical trial with ... Qbeta virus-like particle (VLP) technology. In this first Phase 1 ... candidate and its potential to protect against H1N1 influenza infection ...
Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6
... , BEDFORD, Mass. , Jan. 20 ... vivo imaging from research through medicine, announced today the commercial ... agent for measuring and monitoring cathepsin B activity associated with disease ... B expression is well known as a key biomarker and therapeutic ...
... SAN DIEGO , Jan. 20, 2010 Amylin Pharmaceuticals, Inc. ... the fourth quarter and full year 2009 on Wednesday, January 27, ... Daniel M. Bradbury , Amylin,s president and chief executive officer, will ... results for the fourth quarter and year ended December 31, 2009 ...
Cached Medicine Technology:VisEn Launches New Cat B 680 FAST(TM) Fluorescence Molecular Imaging Agent 2VisEn Launches New Cat B 680 FAST(TM) Fluorescence Molecular Imaging Agent 3Amylin Pharmaceuticals to Webcast Year-End Financial Results 2
... This therapeutic system ... the patient in mind. ... surgery and ongoing therapy, ... low-risk and effective therapy. ...
All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
... only one of the most modern lithotripters available ... from being designed for the treatment of the ... the MODULITH SLX can also be employed for ... equally suitable for the treatment of gallstones or ...
... The MINILITH SL1 developed by STORZ ... of extensive experience in the field of ... of the specific requirements to be met ... therapy, as has been outlined above. The ...
Medicine Products: